Orchestra BioMed Holdings, a biomedical company, has been added to the Russell 3000 and Russell 2000 indexes following the 2026 Russell indexes reconstitution. This inclusion reflects the company's market capitalization ranking among the 4,000 largest U.S. stocks and means it will be tracked by many institutional investors and index funds. Orchestra BioMed is advancing innovative therapies for hypertension and artery disease, with key products in pivotal trials and collaborations with major medical device firms like Medtronic. Being part of these indexes could enhance the company's exposure and attract more investment as it develops its breakthrough medical technologies.
State Street Global Advisors & Affiliates disclosed a reduction in their holdings of DCC plc ordinary shares to 1,193,218 shares, representing 1.39682% of the company. The reduction involved selling 1,544 shares at €62.30 each on June 26, 2026. This ...
The global head-up display (HUD) market is expected to grow from $6.9 billion in 2024 to $13.7 billion by 2030, at a CAGR of 12.8%, fueled by rising demand for digital cockpits and advanced driver assistance systems in vehicles. Asia-Pacific leads wi...
SPR has been named a Top Workplace in Northeast Ohio for the fifth consecutive year, reflecting its strong company culture and rapid growth. Since its first award, SPR has doubled its workforce, seen significant revenue growth from its SPRINT PNS Sys...
A new study analyzing nearly 68,000 US patients found that adoption of adalimumab biosimilars increased significantly after formulary changes, but over 16% of those who switched from Humira reverted back to the original drug. The research highlights ...
Volaris Group has acquired SureView Systems, a UK company specializing in enterprise security monitoring and response software for physical and cyber domains. This acquisition enhances Volaris's security vertical by adding SureView's expertise in phy...
